Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.50 |
| ▸ | PPARG | P37231 | 8/20 | 0.50 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5992779 | 0.92 | PPARA (0.62) | PPARAPPARGCTSCL3MBTL1ACACB | |
| SCHEMBL28874725 | 0.80 | LDHA (0.51) | PPARAPPARGSMN1; SMN2L3MBTL1ACACB | |
| SCHEMBL5991846 | 0.79 | PPARA (0.65) | PPARAPPARGCTSCL3MBTL1ACACB | |
| SCHEMBL27548183 | 0.79 | SMN1; SMN2 (0.44) | PPARAPPARGSMN1; SMN2L3MBTL1ACACB | |
| SCHEMBL6818027 | 0.77 | ESR1 (0.46) | SMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL4755505 | 0.77 | MEN1 (0.45) | PPARAPPARGSMN1; SMN2L3MBTL1ACACB | |
| SCHEMBL947174 | 0.76 | FFAR1 (0.55) | PPARAPPARGSMN1; SMN2L3MBTL1 | |
| SCHEMBL11348091 | 0.76 | EPHX2 (0.48) | PPARAPPARGCTSCSMN1; SMN2L3MBTL1 | |
| SCHEMBL11351977 | 0.76 | PPARG (0.48) | PPARGSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL28305791 | 0.76 | CYP2A6 (0.44) | SMN1; SMN2L3MBTL1ACACBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | ASTRAZENECA AB (SE) | 2003-01-23 | — | — | US | disclosed |
| EP-1237857-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040170-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | GPR119, INSR, IAPP | PPARA 74/4885PPARG 47/4885CTSC 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.